Launch of Coralan? Tablet, an HCN Channel Blocker in Japan

發(fā)布時(shí)間： 2019-11-26 閱讀：862次

分享

Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President and Representative Director: Gyo Sagara;“ONO”) announced today that it has launched Coralan? (generic name: ivabradine hydrochloride)Tablet 2.5mg, 5mg and 7.5mg (“Coralan”), a HCN (hyperpolarization-activated cyclic nucleotidegated) channel blocker, for the treatment of patients with chronic heart failure with sinus rhythm and baseline resting heart rate ≥75 beats per minute (limited to patients receiving standard treatment of chronic heart failure, including β-blocker) in Japan.

Heart failure is defined as a clinical syndrome in which dyspnea, fatigue and edema appear as a result of failure of compensatory function of the cardiac pump due to cardiac dysfunction, resulting in a decrease in exercise tolerance. Chronic heart failure (CHF) is the condition where the situation of heart failure chronically continues, and the number of patients with CHF in Japan is estimated to reach 1.2 million in 2020*1. The drugs used for the treatment of CHF include angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, β-blockers, anti-aldosterone drugs, diuretics, etc. for the purpose of controlling symptoms of patients, preventing hospitalization, and avoiding death in patients with CHF.

In patients with CHF, the heart rate tends to increase to compensate for the inability of the heart to exert sufficient blood volume leading to put more strain on the heart. In addition, it has been shown that higher heart rates have a negative impact on the prognosis in patients with CHF.

In patients with CHF, the heart rate tends to increase to compensate for the inability of the heart to exert sufficient blood volume leading to put more strain on the heart. In addition, it has been shown that higher heart rates have a negative impact on the prognosis in patients with CHF.

Ivabradine has been approved in 124 countries or regions, among which it has been approved in 116 countries for both indications of CHF and chronic stable angina pectoris.

In accordance with the license agreement entered in September 2011 with Servier, ONO has exclusive rights to develop and commercialize Ivabradine in Japan and has been committed to developing the product for the treatment of CHF.